{"id":68745,"date":"2026-02-20T17:22:38","date_gmt":"2026-02-20T17:22:38","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=68745"},"modified":"2026-10-15T10:34:00","modified_gmt":"2026-10-15T10:34:00","slug":"bpc-157","status":"publish","type":"product","link":"https:\/\/medsbase.com\/fr\/product\/bpc-157\/","title":{"rendered":"BPC-157"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">R\u00e9ponse rapide \u2014 Qu'est-ce que le BPC-157 ?<\/h3>\n<p style=\"margin: 0;\"><strong>BPC-157<\/strong> (Body Protection Compound 157) is a 15-amino-acid synthetic pentadecapeptide derived from a protective gastric protein. In published preclinical studies it has shown consistent effects on tendon, ligament, gut, muscle, and vascular tissue recovery via VEGF, nitric oxide, and growth-hormone-receptor signaling. Supplied in 2\u00a0mg to 10\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Ce que vous obtenez avec MedsBase :<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/fr\/reviews\/\">avis clients<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Chaque commande est couverte par notre <a href=\"https:\/\/medsbase.com\/fr\/medsbase-re-shipment-assurance-policy\/\"><strong>Politique de R\u00e9exp\u00e9ditions Garanties<\/strong><\/a> \u2014 si votre colis n'arrive pas dans les 20 jours ouvrables, nous le r\u00e9exp\u00e9dions.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Sp\u00e9cification<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">D\u00e9tail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Num\u00e9ro CAS<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">137525-51-0<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Formule mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">C<sub>62<\/sub>H<sub>98<\/sub>N<sub>16<\/sub>O<sub>22<\/sub><\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Masse mol\u00e9culaire<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1419.55 Da<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>S\u00e9quence<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Forme<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Poudre lyophilis\u00e9e (ou tel que fourni)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Puret\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599 % (v\u00e9rifi\u00e9 par HPLC, COA sur demande)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Stockage<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyophilis\u00e9 : 2\u20138 \u00b0C (r\u00e9frig\u00e9rateur) pour le stock de travail ; \u221220 \u00b0C pour le stockage \u00e0 long terme des flacons non ouverts. Reconstitu\u00e9 : 2\u20138 \u00b0C, \u00e0 utiliser dans ~30 jours. Prot\u00e9ger de la lumi\u00e8re. Ne pas congeler-d\u00e9congeler la solution reconstitu\u00e9e.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Solubilit\u00e9<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Eau bact\u00e9riostatique (recommand\u00e9e) ou eau st\u00e9rile pour des fen\u00eatres d'utilisation plus courtes<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Qu'est-ce que le BPC-157 ?<\/h2>\n<p><strong>BPC-157<\/strong> est l'abr\u00e9viation de <strong>Body Protection Compound 157<\/strong>, a 15-amino-acid synthetic pentadecapeptide originally isolated as a fragment of a larger protective protein found in human gastric juice. Unlike most peptides it is stable in gastric acid, which has made it a frequent subject of oral-administration studies in rodent models alongside the more common subcutaneous route. BPC-157 is one of the most widely studied healing peptides in the preclinical literature, with published work spanning tendon, ligament, gut barrier, skeletal muscle, bone, and vascular tissue. The peptide sequence is GEPPPGKPADDAGLV, molecular weight approximately 1,419\u00a0Da, empirical formula C<sub>62<\/sub>H<sub>98<\/sub>N<sub>16<\/sub>O<sub>22<\/sub>. It is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. For a deep-dive on mechanism, published trial detail, and dosing considerations, see our full <a href=\"https:\/\/medsbase.com\/fr\/bpc-157-peptide-healing-recovery-guide\/\">BPC-157 guide<\/a>. <\/p>\n<h2>M\u00e9canisme d'action \u2014 Trois voies de gu\u00e9rison chevauchantes<\/h2>\n<p>Ce qui diff\u00e9rencie le BPC-157 des peptides \u00e0 voie unique est son <strong>activit\u00e9 simultan\u00e9e sur trois voies de signalisation distinctes<\/strong>, each contributing to the observed tissue-recovery phenotype in published studies:<\/p>\n<ul>\n<li><strong>Angiogen\u00e8se \/ R\u00e9gulation positive du VEGF<\/strong> \u2014 Le BPC-157 r\u00e9gule positivement l'expression du r\u00e9cepteur 2 du facteur de croissance endoth\u00e9lial vasculaire (VEGFR2) dans les tissus l\u00e9s\u00e9s, favorisant la formation de nouveaux capillaires. Cela am\u00e9liore la perfusion locale sur les sites de r\u00e9paration, l'\u00e9tape limitante dans la gu\u00e9rison des tendons, ligaments et muscles.<\/li>\n<li><strong>Voie du monoxyde d'azote (NO)<\/strong> \u2014 Le BPC-157 am\u00e9liore l'activit\u00e9 de la monoxyde d'azote synthase endoth\u00e9liale (eNOS) et prot\u00e8ge l'endoth\u00e9lium vasculaire contre les dommages oxydatifs. Dans les mod\u00e8les rongeurs d'hypertension portale, de vasoconstriction syst\u00e9mique et d'ulc\u00e8res gastriques, cet effet est central dans l'action protectrice du compos\u00e9.<\/li>\n<li><strong>R\u00e9gulation positive des r\u00e9cepteurs de l'hormone de croissance<\/strong> \u2014 Le BPC-157 augmente l'expression des r\u00e9cepteurs de l'hormone de croissance (GHR) sur les fibroblastes et les t\u00e9nocytes, am\u00e9liorant la synth\u00e8se du collag\u00e8ne de type I. Ce m\u00e9canisme est consid\u00e9r\u00e9 comme \u00e9tant \u00e0 l'origine des gains de r\u00e9sistance tendineuse observ\u00e9s dans les mod\u00e8les de transection du tendon d'Achille et du ligament collat\u00e9ral m\u00e9dial.<\/li>\n<\/ul>\n<p>Because these three pathways converge on tissue that has been injured, BPC-157 produces faster and more complete recovery than single-pathway interventions in the same models. It is also notably well tolerated across the range of published doses, with minimal off-target signaling reported in toxicology studies. <\/p>\n<h2>Published Evidence<\/h2>\n<p>BPC-157 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>R\u00e9cup\u00e9ration des l\u00e9sions tendineuses et ligamentaires<\/strong> \u2014 mod\u00e8les murins de section du tendon d'Achille, rupture du ligament collat\u00e9ral m\u00e9dial et d\u00e9chirure de la coiffe des rotateurs (Chang et al., J Appl Physiol 2011 ; Staresinic et al., J Orthop Res 2003)<\/li>\n<li><strong>Gut barrier integrity and ulcer studies<\/strong> \u2014 mod\u00e8les d'ulc\u00e8re gastrique, de colite et de maladie inflammatoire de l'intestin ; l'origine gastrique du BPC-157 est m\u00e9canistiquement pertinente ici (Sikiric et al., Curr Med Chem 2011)<\/li>\n<li><strong>R\u00e9g\u00e9n\u00e9ration musculaire squelettique<\/strong> \u2014 post-injury recovery kinetics, myoblast proliferation, and myotube formation studies<\/li>\n<li><strong>Joint and cartilage studies<\/strong> \u2014 mod\u00e8les murins d'arthrose, composition de la matrice cartilagineuse, inflammation synoviale<\/li>\n<li><strong>Angiogen\u00e8se vasculaire<\/strong> \u2014 formation de nouveaux capillaires et perfusion au niveau des sites tissulaires l\u00e9s\u00e9s<\/li>\n<li><strong>Cicatrisation osseuse<\/strong> \u2014 fracture callus formation in osteotomy and bone-defect study models<\/li>\n<li><strong>Comparative recovery<\/strong> \u2014 \u00e9valuation comparative avec d'autres peptides cicatrisants, en particulier <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500 (Thymosine B\u00eata-4)<\/a> comme comparateur syst\u00e9mique de cicatrisation canonique. Voir le <a href=\"https:\/\/medsbase.com\/fr\/bpc-157-vs-tb-500-comparison-guide\/\">comparaison BPC-157 vs TB-500<\/a> pour une comparaison c\u00f4te \u00e0 c\u00f4te compl\u00e8te.<\/li>\n<\/ul>\n<p>Pour un contexte plus large sur la place du BPC-157 dans le paysage des peptides de gu\u00e9rison, consultez <a href=\"https:\/\/medsbase.com\/fr\/best-peptides-for-muscle-recovery\/\">les meilleurs peptides pour la r\u00e9cup\u00e9ration musculaire<\/a> l'article sur les clusters et <a href=\"https:\/\/medsbase.com\/fr\/ghk-cu\/\">le peptide de cuivre GHK-Cu<\/a> as a complementary anti-aging compound. Browse the full <a href=\"https:\/\/medsbase.com\/fr\/peptides\/\">catalogue de peptides<\/a> pour les compos\u00e9s associ\u00e9s. <\/p>\n<h2>Forces et concentrations disponibles<\/h2>\n<p>MedsBase propose le BPC-157 dans les tailles de flacons lyophilis\u00e9s suivantes. Chaque variante est exp\u00e9di\u00e9e en formats de 10, 20 et 30 flacons avec des instructions compl\u00e8tes de reconstitution :<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Concentration du flacon<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Cas d'utilisation typique<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Tailles de conditionnement<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>2 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Short protocols, pilot dosing, titration<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength, most commonly ordered<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>10\u00a0mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Extended protocols, lowest per-mg cost<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10, 20 ou 30 flacons<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>All three strengths are the same chemical form (lyophilized powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when users want to minimise injection volume in rodent protocols. <\/p>\n<h2>Comparaison \u2014 BPC-157 vs TB-500<\/h2>\n<p>BPC-157 et <a href=\"https:\/\/medsbase.com\/fr\/tb-500\/\">TB-500<\/a> are the two most-cited healing peptides. They are often studied in parallel because they act via complementary, largely non-overlapping mechanisms. Many preclinical protocols combine them rather than using either alone. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Crit\u00e8re<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">BPC-157<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">TB-500 (Thymosine B\u00eata-4)<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Longueur<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">15 acides amin\u00e9s (pentad\u00e9capeptide)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">43 acides amin\u00e9s (peptide thymique)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>M\u00e9canisme principal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">VEGF + NO + r\u00e9gulation positive des r\u00e9cepteurs GH<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">S\u00e9questration de G-actine, migration cellulaire<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Distribution<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Plus localis\u00e9e au site d'injection<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Syst\u00e9mique, se distribue largement<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Dose typique<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">250\u2013500 mcg, 1\u20132 fois par jour<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">2\u20132,5 mg, 2 fois par semaine<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Tendon, ligament, barri\u00e8re intestinale<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Cardiaque, musculaire syst\u00e9mique, vasculaire<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Empilement<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Commonly co-administered with TB-500 in studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Commonly co-administered with BPC-157 in studies<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>For a full methodological comparison including dosing protocols and when users pick one over the other, read <a href=\"https:\/\/medsbase.com\/fr\/bpc-157-vs-tb-500-comparison-guide\/\">BPC-157 vs TB-500 : quel peptide de gu\u00e9rison pour votre objectif de r\u00e9cup\u00e9ration<\/a>. <\/p>\n<h2>Stockage et reconstitution<\/h2>\n<p><strong>Avant la reconstitution :<\/strong> conserver les flacons lyophilis\u00e9s au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C dans leur emballage d'origine. Le BPC-157 lyophilis\u00e9 est stable dans ces conditions jusqu'\u00e0 36 mois. \u00c9vitez les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation de la poudre. <strong>Proc\u00e9dure de reconstitution :<\/strong> injecter de l'eau bact\u00e9riostatique le long de la paroi lat\u00e9rale du flacon de peptide (pas directement sur le g\u00e2teau lyophilis\u00e9) selon le tableau de dilution ci-dessus. Tourner doucement \u2014 ne pas <strong>re\u00e7oit pas<\/strong> secouer \u2014 et laisser 2 \u00e0 5 minutes pour une dissolution compl\u00e8te. Une solution correctement reconstitu\u00e9e doit \u00eatre claire et incolore. <strong>Apr\u00e8s reconstitution :<\/strong> conserver au r\u00e9frig\u00e9rateur \u00e0 2\u20138 \u00b0C et utiliser dans les 30 jours pour une stabilit\u00e9 optimale. Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de cong\u00e9lation-d\u00e9cong\u00e9lation d\u00e9gradent l'int\u00e9grit\u00e9 du peptide. Jeter tout flacon pr\u00e9sentant de la turbidit\u00e9, un pr\u00e9cipit\u00e9 ou une d\u00e9coloration. <\/p>\n<h2 id=\"faqs\">Questions fr\u00e9quemment pos\u00e9es<\/h2>\n<h3>What is BPC-157 used for in studies?<\/h3>\n<p>BPC-157 is used in studies investigating tendon and ligament healing, gut barrier integrity, skeletal muscle recovery, vascular angiogenesis, anti-inflammatory signaling, and bone healing. It is <strong>re\u00e7oit pas<\/strong> FDA-approved and is sold here strictly for clinical studies use only. <\/p>\n<h3>En quoi le BPC-157 est-il diff\u00e9rent du TB-500 ?<\/h3>\n<p>BPC-157 is a 15-amino-acid pentadecapeptide derived from gastric juice, acting mostly locally via VEGF, nitric oxide, and growth-hormone-receptor pathways. TB-500 is a 43-amino-acid thymic peptide that acts systemically via G-actin binding and cell migration. The two are often co-administered in studies because their mechanisms are complementary rather than overlapping. <\/p>\n<h3>What is the typical BPC-157 dose?<\/h3>\n<p>Les protocoles pr\u00e9cliniques publi\u00e9s utilisent g\u00e9n\u00e9ralement 250\u2013500 mcg par administration, administr\u00e9s une ou deux fois par jour pendant des cycles de 4 \u00e0 8 semaines. Un flacon de 5 mg reconstitu\u00e9 avec 2,0 mL d'eau bact\u00e9riostatique donne une concentration de 2,5 mg\/mL \u2014 10 crans sur une seringue U-100 \u00e9quivalent \u00e0 250 mcg. <\/p>\n<h3>Le BPC-157 est-il approuv\u00e9 par la FDA ?<\/h3>\n<p>No. BPC-157 is not approved by the FDA, EMA, MHRA, or any other regulator for human therapeutic use. <\/p>\n<h3>Comment conserver le BPC-157 ?<\/h3>\n<p>Flacons lyophilis\u00e9s : r\u00e9frig\u00e9r\u00e9s \u00e0 2\u20138 \u00b0C dans leur emballage d'origine, stables jusqu'\u00e0 36 mois. Solution reconstitu\u00e9e : r\u00e9frig\u00e9r\u00e9e \u00e0 2\u20138 \u00b0C, \u00e0 utiliser dans les 30 jours. Ne pas congeler la solution reconstitu\u00e9e \u2014 les cycles de gel-d\u00e9gradation alt\u00e8rent le peptide. <\/p>\n<h3>Comment reconstituer le BPC-157 ?<\/h3>\n<p>Suivez le tableau de r\u00e9f\u00e9rence de reconstitution ci-dessus. Ajoutez de l'eau bact\u00e9riostatique le long de la paroi du flacon (pas directement sur la poudre lyophilis\u00e9e), agitez doucement et laissez dissoudre compl\u00e8tement pendant 2 \u00e0 5 minutes. Ne <strong>re\u00e7oit pas<\/strong> secouez pas le flacon. <\/p>\n<h3>Quelles sont les dosages disponibles chez MedsBase ?<\/h3>\n<p>MedsBase propose du BPC-157 en flacons lyophilis\u00e9s de 2 mg, 5 mg et 10 mg. Chaque dosage est disponible en packs de 10, 20 ou 30 flacons. Tous les flacons ont une puret\u00e9 HPLC de 99 %+ et un certificat d'analyse disponible sur demande. <\/p>\n<h3>Can BPC-157 and TB-500 be stacked in studies?<\/h3>\n<p>Yes. BPC-157 and TB-500 are frequently co-administered in preclinical studies because their mechanisms are complementary. BPC-157 acts mostly locally via growth-factor upregulation; TB-500 acts systemically via G-actin binding and cell migration. Combined protocols are described in our <a href=\"https:\/\/medsbase.com\/fr\/bpc-157-vs-tb-500-comparison-guide\/\">guide comparatif<\/a>. <\/p>\n<h3>Does BPC-157 cause side reported effects?<\/h3>\n<p>Published preclinical studies across rodent species has reported a notably clean safety profile at typical doses, with no consistent off-target signals and good tolerability. Long-term human safety data are not available because human trials have not been completed. <\/p>\n<h3>What is the difference between oral and injectable BPC-157 in studies?<\/h3>\n<p>BPC-157 is unusually stable in gastric acid due to its gastric-juice-derived origin, so oral administration is feasible in rodent protocols (unlike most peptides). Subcutaneous injection remains the most common administration route in the literature because it produces more reproducible plasma concentrations. <\/p>\n<h3>Quelle est la demi-vie du BPC-157 ?<\/h3>\n<p>In preclinical studies, BPC-157 has an estimated plasma half-life of approximately 4 hours following subcutaneous administration. Oral route studies in rodent models suggest shorter systemic clearance but sustained local effects within the gastrointestinal tract, attributed to the peptide&#8217;s unusual acid-stability. <\/p>\n<h3>How long does BPC-157 take to show effects in preclinical studies?<\/h3>\n<p>Most preclinical studies using BPC-157 in tendon, ligament, and gut injury models report measurable tissue-level changes within 7\u201314 days. The time-course varies with the study model, injury severity, route of administration, and dose used in the study design. <\/p>\n<h3>Puis-je commander du BPC-157 pour une livraison internationale ?<\/h3>\n<p>Oui. MedsBase exp\u00e9die le BPC-157 dans le monde entier depuis notre r\u00e9seau d\u00e9di\u00e9 \u00e0 l'exp\u00e9dition de peptides. Les commandes de peptides uniquement sont \u00e9ligibles \u00e0 notre service d'exp\u00e9dition de peptides autonome. Toutes les commandes sont exp\u00e9di\u00e9es dans un emballage \u00e0 temp\u00e9rature contr\u00f4l\u00e9e avec un suivi complet. <\/p>\n<p class=\"medsbase-bundle-link-2026-05-01\" data-marker=\"mb-bundle-link-peptide-healing-stack\">Les protocoles de BPC-157 pour la r\u00e9cup\u00e9ration des tendons, ligaments et tissus mous l'associent g\u00e9n\u00e9ralement au TB-500 pour des effets angiog\u00e9niques + cytosquelettiques synergiques ; pour le r\u00e9gime group\u00e9, consultez notre <a href=\"\/fr\/peptide-healing-stack\/\">Stack de gu\u00e9rison par peptides (BPC-157 5 mg + TB-500 5 mg + eau bact\u00e9riostatique)<\/a> avec \u00e0 la fois des flacons lyophilis\u00e9s et de l'eau de reconstitution dans un seul colis au tarif d'exp\u00e9dition de peptides de $0.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Recovery and Performance<\/h2>\n<ul>\n<li><a href=\"\/fr\/tb-500\/\"><strong>TB-500<\/strong><\/a> \u2014 Thymosin Beta-4 fragment \u2014 soft tissue and vascular recovery<\/li>\n<li><a href=\"\/fr\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Agoniste s\u00e9lectif de la ghr\u00e9line \u2014 pic d'hormone de croissance propre sans cortisol\/prolactine<\/li>\n<li><a href=\"\/fr\/cjc-1295-with-dac\/\"><strong>CJC-1295 avec DAC<\/strong><\/a> \u2014 Analogue de GHRH avec demi-vie prolong\u00e9e<\/li>\n<li><a href=\"\/fr\/ghk-cu\/\"><strong>GHK-Cu<\/strong><\/a> \u2014 Copper peptide \u2014 skin and connective tissue regeneration<\/li>\n<li><a href=\"\/fr\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 Long-R3 IGF-1 analog \u2014 anabolic \/ regenerative support<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Pour en savoir plus<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Learn the science behind this peptide<\/strong><\/p>\n<p style=\"margin: 0;\">Lisez notre guide complet bas\u00e9 sur des preuves : <a href=\"https:\/\/medsbase.com\/fr\/bpc-157-peptide-healing-recovery-guide\/\"><strong>BPC-157 \u2014 m\u00e9canisme, donn\u00e9es d'essais et perspectives<\/strong><\/a>. Covers mechanism of action, published study data, typical dosing ranges, reconstitution protocols, stacking considerations, and safety\/contraindication notes.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Favorise la r\u00e9g\u00e9n\u00e9ration cellulaire<br \/>\n\u2705 Am\u00e9liore la mod\u00e9lisation tissulaire<br \/>\n\u2705 Stimule l'activit\u00e9 des fibroblastes<br \/>\n\u2705 Active la signalisation angiog\u00e9nique<br \/>\n\u2705 Am\u00e9liore la stabilit\u00e9 de la matrice extracellulaire<\/p>\n<p><strong>BPC-157<\/strong> contient un compos\u00e9 peptidique synth\u00e9tique.<\/p>","protected":false},"featured_media":70942,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[5440,5430,5441],"class_list":["post-68745","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-bpc-157","product_tag-bpc-157-peptide","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product\/68745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/comments?post=68745"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media\/70942"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/media?parent=68745"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_brand?post=68745"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_cat?post=68745"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/fr\/wp-json\/wp\/v2\/product_tag?post=68745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}